Seattle Times science reporter Sandi Doughton, Dr. Celestia Higano, professor at the University of Washington School of Medicine, and David Miller, CEO of Biotech Stock Research conducted a live Q&A Tuesday, May 4, 2010, to discuss the FDA approval of the prostate cancer vaccine, Provenge, which was created by Seattle-based biotech firm Dendreon.

Seattle Times science reporter Sandi Doughton, Dr. Celestia Higano, professor at the University of Washington School of Medicine, and David Miller, CEO of Biotech Stock Research conducted a live Q&A Tuesday, May 4, 2010, to discuss the FDA approval of the prostate cancer vaccine, Provenge, which was created by Seattle-based biotech firm Dendreon. Higano, a prostate specialist at Seattle Cancer Care Alliance, helped oversee clinical trials for Provenge. Miller has been covering Dendreon as an independent analyst for nearly nine years.

Dr. Celestia Higano, professor, University of Washington School of Medicine

Dr. Higano received her M.D. from the University of Massachusetts. She is a member of the Fred Hutchinson Cancer Research Center. In 1995, Higano began to build a team of researchers that has become known as the Prostate Cancer Clinical Research Program. Her research focuses on the use of intermittent androgen deprivation in men with prostate cancer, the effects of androgen deprivation on men with non-metastatic disease, novel targeted therapies, chemotherapy, and immunotherapy.

David Miller, President/CEO, Biotech Stock Research

    Most Read Stories

Miller is an acknowledged expert on biotech investing. With a background as a company CEO, technical analyst, and market commentator, he provides analysis of the sector and companies in his coverage universe. Miller has been covering Dendreon as an analyst for nearly nine years and has attended all of their major scientific presentations, including the 2007 FDA Advisory panel hearing. He was quoted in the April 29 New York Times story F.D.A. Approves ‘Vaccine’ to Fight Prostate Cancer’ on his prediction that sales of Provenge would reach $1 billion annually within two or three years.